| Teresa A Muller, APRN-C | |
|
5885 Sunnybrook Dr Ste L-200, Cardiovascular Associates Pc, Sioux City, IA 51106-4203 | |
| (712) 239-4702 | |
| (712) 239-0616 |
| Full Name | Teresa A Muller |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 23 Years |
| Location | 5885 Sunnybrook Dr Ste L-200, Sioux City, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033281613 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 110621 (Nebraska) | Primary |
| 363LF0000X | Nurse Practitioner - Family | A-104191 (Iowa) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Lukes Regional Medical Center | Sioux city, IA | Hospital |
| Cherokee Regional Medical Center | Cherokee, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwest Iowa Hospital Corporation | 0749198026 | 46 |
News Archive
An essential aspect of oral surgery is controlling the patient's pain following a procedure. The goal is to relieve pain and promote a rapid recovery, without opioid side effects. An initial study shows that Dyloject, a new intravenous form of the drug diclofenac, has promise for achieving these goals.
ConjuChem Biotechnologies Inc. announced today that the U.S. Patent & Trademark Office (USPTO) has issued a Right of Appeal Notice (Final Office Action) in the inter partes reexamination of Patent No. 6,924,264. The patent, entitled "Modified Exendins and Exendin Agonists," was issued in August 2005 and is assigned to Amylin Pharmaceuticals, Inc. The Action once again rejected all the subject claims for obviousness and/or lack of novelty. The inter partes reexamination in the USPTO does not involve any of ConjuChem's patents.
Advances in medical diagnostic technology will likely allow individuals to perform preliminary medical diagnoses themselves, in their own home, in the future.
Researchers from Columbia University Medical Center have found that, for many patients, an initial diagnosis of "acute kidney injury" may have been inaccurate.
Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.
› Verified 7 days ago
| Entity Name | Northwest Iowa Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215962550 PECOS PAC ID: 0749198026 Enrollment ID: O20040217000619 |
News Archive
An essential aspect of oral surgery is controlling the patient's pain following a procedure. The goal is to relieve pain and promote a rapid recovery, without opioid side effects. An initial study shows that Dyloject, a new intravenous form of the drug diclofenac, has promise for achieving these goals.
ConjuChem Biotechnologies Inc. announced today that the U.S. Patent & Trademark Office (USPTO) has issued a Right of Appeal Notice (Final Office Action) in the inter partes reexamination of Patent No. 6,924,264. The patent, entitled "Modified Exendins and Exendin Agonists," was issued in August 2005 and is assigned to Amylin Pharmaceuticals, Inc. The Action once again rejected all the subject claims for obviousness and/or lack of novelty. The inter partes reexamination in the USPTO does not involve any of ConjuChem's patents.
Advances in medical diagnostic technology will likely allow individuals to perform preliminary medical diagnoses themselves, in their own home, in the future.
Researchers from Columbia University Medical Center have found that, for many patients, an initial diagnosis of "acute kidney injury" may have been inaccurate.
Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Teresa A Muller, APRN-C Po Box 3128, Cardiovascular Associates Pc, Sioux City, IA 51102-3128 Ph: (712) 239-4702 | Teresa A Muller, APRN-C 5885 Sunnybrook Dr Ste L-200, Cardiovascular Associates Pc, Sioux City, IA 51106-4203 Ph: (712) 239-4702 |
News Archive
An essential aspect of oral surgery is controlling the patient's pain following a procedure. The goal is to relieve pain and promote a rapid recovery, without opioid side effects. An initial study shows that Dyloject, a new intravenous form of the drug diclofenac, has promise for achieving these goals.
ConjuChem Biotechnologies Inc. announced today that the U.S. Patent & Trademark Office (USPTO) has issued a Right of Appeal Notice (Final Office Action) in the inter partes reexamination of Patent No. 6,924,264. The patent, entitled "Modified Exendins and Exendin Agonists," was issued in August 2005 and is assigned to Amylin Pharmaceuticals, Inc. The Action once again rejected all the subject claims for obviousness and/or lack of novelty. The inter partes reexamination in the USPTO does not involve any of ConjuChem's patents.
Advances in medical diagnostic technology will likely allow individuals to perform preliminary medical diagnoses themselves, in their own home, in the future.
Researchers from Columbia University Medical Center have found that, for many patients, an initial diagnosis of "acute kidney injury" may have been inaccurate.
Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.
› Verified 7 days ago
Mary Ann Gengler, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3500 Singing Hills Blvd Ste 200, Sioux City, IA 51106 Phone: 605-217-7246 Fax: 605-217-4878 | |
Courtney Jean Marie Mayo, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2600 Outer Dr N, Sioux City, IA 51104 Phone: 712-239-3300 Fax: 712-239-8201 | |
Cindy L Schol, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2800 Pierce St, Ste 315, Sioux City, IA 51104 Phone: 712-279-3411 Fax: 712-279-7023 | |
Lindsey Renee Dutler, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 309 Cook St, Sioux City, IA 51103 Phone: 712-224-7223 | |
Mrs. Erin Ann Hodgson, DNP, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3549 Southern Hills Dr, Sioux City, IA 51106 Phone: 712-274-6729 Fax: 712-274-6744 | |
Kirsten Marie Nedved, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 801 5th St, Sioux City, IA 51101 Phone: 712-294-7020 | |
Trudy Jean Bader, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4300 Hamilton Blvd, Sioux City, IA 51104 Phone: 712-233-4144 |